Globus Medical, Inc.
NYSE:GMEDMedical - Devices
-$2.10 today
- Market cap
- $9.34B
- Beta
- 0.95
- P/E (TTM)
- 17.4
- EPS (TTM)
- $4.33
Volume 1.43M
Average 1.45M
GMED Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Globus Medical, Inc.NYSE: GMED
Net Change in Cash · Q2 FY2026 · quarter ended Jun 2026
Net change in cash dips below year-ago levels
Q2 FY2026 net change in cash of $53.21M (cash outflow) fell 77.0% year over year, behind the +253.8% change in trailing-twelve-month net change in cash. Over 3 fiscal years it compounded at +82.3% a year.
Context
- Net change in cash amounted to 8.8% of revenue in FY2025, down 3.8 pp from a year earlier.
- Net change in cash increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -77.0% toward the trailing-twelve-month pace of +253.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- (258.28M) USD
- Year-over-year change
- -181.4%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (258.28M) | -181.4% |
| FY2024 | 2024-12-31 | 317.15M | +0.1% |
| FY2023 | 2023-12-31 | 316.83M | +843.7% |
| FY2022 | 2022-12-31 | (42.6M) | +8.0% |
| FY2021 | 2021-12-31 | (46.33M) | — |
Net Change in Cash vs competitors
How GMED compares with its peers on the latest reported figures
- GMED's LTM Jun 2026 net change in cash of $278.3M is the 2nd largest of the 10 companies compared; the peer median is $7.65M.
- Its year-over-year change of +253.8% is the 3rd highest of 10, against a peer median of -119.6%.
- Net change in cash amounts to 8.8% of revenue for GMED, versus a peer median of 3.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.02B | +102.8% | — | 3.9% | |
| LTM Jun 2026 | $278.3M | +253.8% | +82.3% | 8.8% | |
| LTM Jun 2026 | $146.9M | -207.4% | — | 1.7% | |
| FY2025 | $62M | -119.6% | -59.6% | 1.0% | |
| LTM Mar 2026 | $60.42M | +95.0% | -74.4% | 7.3% | |
| LTM Mar 2026 | $21.18M | -278.5% | — | 8.7% | |
| LTM Mar 2026 | $13.33M | -245.6% | — | 1.7% | |
| LTM Mar 2026 | $13.04M | +650.1% | — | 2.3% | |
| LTM Mar 2026 | $7.65M | -183.7% | — | 3.7% | |
| LTM Mar 2026 | $6.72M | +728.9% | +73.7% | 5.5% | |
| Peer median (excluding GMED) | $7.65M | -119.6% | -59.6% | 3.7% | |
Competitors are the stored peer set for GMED. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 149.19M | 190.17M | 122.87M | 102.98M | 537.87M |
| Depreciation & Amortization | 69.87M | 68.25M | 144.73M | 254.02M | 276.84M |
| Deferred Income Tax | (17.62M) | (22.22M) | (57.79M) | (125.9M) | 18.63M |
| Stock-Based Compensation | 30.59M | 32.81M | 52.74M | 54.19M | 49.78M |
| Change in Working Capital | (17.25M) | (105.26M) | (116.6M) | (97.55M) | (82.71M) |
| Accounts Receivables | (25.9M) | (50.84M) | (49.91M) | (78.06M) | (52.18M) |
| Inventory | (11.97M) | (61.75M) | (70.33M) | (29.86M) | (17.6M) |
| Accounts Payables | 3.68M | 14.42M | (14.22M) | 17.66M | 8.49M |
| Other Working Capital | 16.93M | (7.09M) | 17.87M | (7.3M) | (21.42M) |
| Other Non-Cash Items | 61.5M | 14.72M | 97.54M | 332.9M | (46.96M) |
| Operating Cash Flow | 276.27M | 178.47M | 243.5M | 520.64M | 753.45M |
| Capital Expenditures | (56.9M) | (74.05M) | (78.27M) | (115.43M) | (164.68M) |
| Acquisitions (Net) | (34.49M) | (31.44M) | (296.03M) | (17.64M) | 13.46M |
| Purchases of Investments | (622.36M) | (419.53M) | (100.64M) | (113.5M) | (107.53M) |
| Sales of Investments | 337.81M | 414.65M | 777.91M | 70.52M | 179.49M |
| Other Investing Activities | 0 | 0 | 0 | 0 | (275.75M) |
| Investing Cash Flow | (375.94M) | (110.36M) | 302.97M | (176.05M) | (355.01M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | (144.49M) | (225.56M) | (85.79M) | (300.45M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 54.15M | 34.53M | (6.26M) | 58.09M | (378.71M) |
| Financing Cash Flow | 54.15M | (109.96M) | (231.82M) | (27.7M) | (679.16M) |
| Effect of Forex Changes | (810K) | (747K) | 2.18M | 255K | 22.45M |
| Net Change in Cash | (46.33M) | (42.6M) | 316.83M | 317.15M | (258.28M) |
| Free Cash Flow | 219.38M | 104.42M | 165.23M | 405.21M | 588.77M |
Globus Medical, Inc.
NYSE:GMED
Intrinsic Alpha fair value
Locked
Current Price
$70.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.